Status:
COMPLETED
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Lead Sponsor:
Faes Farma, S.A.
Collaborating Sponsors:
ORA, Inc.
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
Eligibility Criteria
Inclusion
- Key
- be at least 18 years old
- be willing and able to avoid all disallowed medications and contact lenses
- must have a pregnancy test if of childbearing potential
- must be able to read an eye chart from 10 feet away
- Key
Exclusion
- must not have any allergies to the study medications
- must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
- must not have used immunotherapy in the last 2 years
- must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial
Key Trial Info
Start Date :
July 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 11 2017
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT03231969
Start Date
July 20 2017
End Date
October 11 2017
Last Update
March 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ora Clinical Research Center
Andover, Massachusetts, United States, 01810